4.5 Article

Leukocyte-associated immunoglobulin-like receptor 1 promotes tumorigenesis in RCC

Journal

ONCOLOGY REPORTS
Volume 41, Issue 2, Pages 1293-1303

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/or.2018.6875

Keywords

leukocyte-associated immunoglobulin-like receptor 1; LAIR1; renal cell carcinoma; tissue-exudative extracellular vesicles

Categories

Funding

  1. Project for Cancer Research and Therapeutic Evolution from the Japan Agency for Medical Research and Development (AMED) [18cm0106405h0003]

Ask authors/readers for more resources

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90-95% of cases. We previously reported a novel method that enables direct extraction of extracellular vesicles (EVs) from surgically resected viable tissues, yielding what we term tissue-exudative extracellular vesicles (Te-EVs). Quantitative LC/MS analysis identified 3,871 proteins in Te-EVs, among which leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) was highly enriched in tumor Te-EVs. In the present study, we found that LAIR1 was significantly upregulated in clinical specimens of human RCC tumor tissues compared to that noted in adjacent non-cancerous renal tissues as determined by quantitative PCR analysis. LAIR1 overexpression resulted in accelerated cell proliferation and tumor growth in RCC cells. Moreover, knockdown of LAIR1 using siRNA significantly inhibited cell proliferation in RCC cells. Mechanistically, LAIR1 upregulated the phosphorylation status of Akt, which in turn increased cell proliferation in RCC cells. In clinical RCC specimens, RCC patients with high LAIR1 mRNA expression showed poor progression-free survival compared to those with low LAIR1 expression. These findings indicate that LAIR1 promotes tumorigenesis in RCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer

Koji Hatano, Tohru Yoneyama, Shingo Hatakeyama, Eisuke Tomiyama, Mutsumi Tsuchiya, Mitsuhisa Nishimoto, Kazuhiro Yoshimura, Eiji Miyoshi, Hirotsugu Uemura, Chikara Ohyama, Norio Nonomura, Kazutoshi Fujita

Summary: By simultaneously analyzing α2,3-Sia-PSA and α1,6-Fuc-PSA, the SF index can effectively differentiate HGPC, providing valuable information for decision making on prostate biopsy in men with abnormal PSA levels.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers

Takeshi Ujike, Motohide Uemura, Taigo Kato, Koji Hatano, Atsunari Kawashima, Akira Nagahara, Kazutoshi Fujita, Ryoichi Imamura, Norio Nonomura

Summary: This study assessed the diagnostic validity of a CAD system for bone scans in RCC patients and developed a novel diagnostic model based on the combination of ANN values and ICTP. The model showed high accuracy in detecting bone metastases.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide

Saizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, Mamoru Hamaguchi, Ken Kuwahara, Mamoru Hashimoto, Shogo Adomi, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Hirotsugu Uemura

Summary: Switching from enzalutamide or apalutamide to darolutamide may be an effective therapeutic option for patients with non-metastatic castration-resistant prostate cancer. This retrospective study demonstrated that approximately 55.5% of patients had a PSA decline >50% after switching to darolutamide, with an average PSA decline of 73%.

CANCER MEDICINE (2023)

Article Oncology

Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma

Mamoru Hashimoto, Kazutoshi Fujita, Eisuke Tomiyama, Saizo Fujimoto, Shogo Adomi, Eri Banno, Takafumi Minami, Tetsuya Takao, Masahiro Nozawa, Hiroaki Fushimi, Kazuhiro Yoshimura, Norio Nonomura, Hirotsugu Uemura

Summary: This study investigated the relationship between nectin-4 and HER2 and EGFR in patients with upper urinary tract urothelial carcinoma (UTUC). The results showed high expression of HER2, EGFR, and nectin-4 in UTUC patients. Combination targeted therapy for HER2, EGFR, and nectin-4 may be an effective treatment option for UTUC patients.

ANTICANCER RESEARCH (2023)

Article Oncology

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Toshiki Oka, Koji Hatano, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Eisuke Tomiyama, Yu Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Norio Nonomura

Summary: This study analyzed patients with castration-resistant prostate cancer (CRPC) who received enzalutamide as first-line therapy. The results showed that lymph node metastasis and time to CRPC can predict the PSA response rate and PSA-progression-free survival of patients treated with enzalutamide.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Urology & Nephrology

Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy

Satoshi Katayama, Benjamin Pradere, Nico C. Grossman, Aaron M. Potretzke, Stephen A. Boorjian, Alireza Ghoreifi, Sia Daneshmand, Hooman Djaladat, John P. Sfakianos, Andrea Mari, Zine-Eddine Khene, David D'Andrea, Nozomi Hayakawa, Alberto Breda, Matteo Fontana, Kazutoshi Fujita, Alessandro Antonelli, Thomas van Doeveren, Christina Steinbach, Keiichiro Mori, Ekaterina Laukhtina, Morgan Roupret, Vitaly Margulis, Pierre Karakiewicz, Motoo Araki, Eva Comperat, Yasutomo Nasu, Shahrokh F. Shariat

Summary: The technical limitations of ureteroscopic biopsy are believed to contribute to the high upgrading rate in upper tract urothelial carcinoma (UTUC). However, the impact of tumor specific factors on upgrading has not been investigated. This study found that high-grade and low-grade biopsy results on ureteroscopy are associated with different biological and clinical features of UTUC tumors.

INTERNATIONAL JOURNAL OF UROLOGY (2023)

Article Urology & Nephrology

Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study

Maximilian Pallauf, David D'Andrea, Frederik Koenig, Ekaterina Laukhtina, Takafumi Yanagisawa, Morgan Roupret, Siamak Daneshmand, Hooman Djaladat, Alireza Ghoreifi, Francesco Soria, Kazutoshi Fujita, Stephen A. Boorjian, Aaron M. Potretzke, Andrea Mari, Mathieu Roumiguie, Alessandro Antonelli, Alberto Bianchi, Zine-Eddine Khene, John P. Sfakianos, Marcus Jamil, Joost L. Boormans, Jay D. Raman, Nico C. Grossmann, Alberto Breda, Axel Heidenreich, Francesco Del Giudice, Nirmish Singla, Shahrokh F. Shariat, Benjamin Pradere

Summary: This study evaluated the diagnostic accuracy of conventional cross-sectional imaging for lymph node staging in upper tract urothelial cancer and found low sensitivity. Therefore, lymph node dissection should be performed during surgery to obtain accurate staging information.

JOURNAL OF UROLOGY (2023)

Article Oncology

Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study

Takero Hirata, Osamu Suzuki, Keisuke Otani, Akimitsu Miyake, Keisuke Tamari, Yuji Seo, Fumiaki Isohashi, Naoki Kai, Koji Hatano, Kazutoshi Fujita, Motohide Uemura, Ryoichi Imamura, Setsuo Tamenaga, Yutaro Yoshino, Yasutoshi Fumimoto, Yasuo Yoshioka, Norio Nonomura, Kazuhiko Ogawa

Summary: This study evaluated the toxicity and efficacy of different SBRT doses for PCa and selected an optimal dose. The results showed that an SBRT dose of 35 Gy per 5 fractions is less likely to cause adverse events than 37.5 and 40 Gy doses in PCa patients.

ACTA ONCOLOGICA (2023)

Review Oncology

The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome

Kazutoshi Fujita, Makoto Matsushita, Marco A. A. De Velasco, Koji Hatano, Takafumi Minami, Norio Nonomura, Hirotsugu Uemura

Summary: The gut microbiome plays a crucial role in the development of diseases like prostate cancer. Gut dysbiosis caused by factors like diet leads to the leakage of gut bacterial metabolites, resulting in prostate cancer growth. Lifestyle factors, especially diet, impact the gut microbiome and are associated with prostate cancer risk. Alterations in the gut microbiome have been identified in patients with prostate cancer, highlighting the importance of considering the gut-prostate axis in screening and treating prostate cancer patients.

CANCERS (2023)

Article Oncology

Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis

Nico C. Grossmann, Francesco Soria, Tristan Juvet, Aaron M. Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekaterina Laukhtina, Pawel Rajwa, Maximillian Pallauf, Cedric Poyet, Giovanni E. Cacciamani, Thomas van Doeveren, Joost L. Boormans, Alessandro Antonelli, Marcus Jamil, Firas Abdollah, Guillaume Ploussard, Axel Heidenreich, Enno Storz, Siamak Daneshmand, Stephen A. Boorjian, Morgan Roupret, Michael Rink, Shahrokh F. Shariat, Benjamin Pradere

Summary: The study compared perioperative and oncologic outcomes among patients who underwent open, laparoscopic, and robotic RNU for non-metastatic upper urinary tract urothelial carcinoma. The results showed worse bladder recurrence-free survival in patients who had laparoscopic and robotic RNU compared to open RNU. However, recurrence-free, cancer-specific, and overall survival were similar between the three surgical approaches. Laparoscopic and robotic RNU were associated with shorter hospital stay and fewer major postoperative complications. Further research is needed to investigate the factors responsible for the inferior bladder recurrence-free survival in patients treated with minimally invasive techniques.

CANCERS (2023)

Article Pathology

Deep Learning-Based Differential Diagnosis of Follicular Thyroid Tumors Using Histopathological Images

Satoshi Nojima, Tokimu Kadoi, Ayana Suzuki, Chiharu Kato, Shoichi Ishida, Kansuke Kido, Kazutoshi Fujita, Yasushi Okuno, Mitsuyoshi Hirokawa, Kei Terayama, Eiichi Morii

Summary: Deep learning systems have been developed to differentiate between follicular thyroid carcinoma and follicular adenoma based on histopathological assessment. The results show that the systems can predict the risk of recurrence, vascular invasion, and wide capsular invasion with a certain level of accuracy based on random views of tumor tissue histology.

MODERN PATHOLOGY (2023)

Article Urology & Nephrology

External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy

Takafumi Minami, Kazutoshi Fujita, Mamoru Hashimoto, Mitsuhisa Nishimoto, Shogo Adomi, Eri Banno, Masahiro Nozawa, Kazuhiro Nose, Kazuhiro Yoshimura, Masahiro Inada, Masaki Yokokawa, Kiyoshi Nakamatsu, Hirotsugu Uemura

Summary: Patients with prostate cancer treated with brachytherapy may have an increased risk of developing bladder cancer, especially those who smoke heavily and receive external beam radiotherapy as part of their treatment.

WORLD JOURNAL OF UROLOGY (2023)

Review Andrology

Emerging Relationship between the Gut Microbiome and Prostate Cancer

Makoto Matsushita, Kazutoshi Fujita, Koji Hatano, Marco A. De Velasco, Akira Tsujimura, Hirotsugu Uemura, Norio Nonomura

Summary: The gut microbiota, influenced by both environmental and genetic factors, has been found to have a significant impact on human health. Research has shown a close association between the gut microbiome and various non-intestinal diseases, particularly in the field of cancer biology and therapy. Prostate cancer cells are directly affected by the microbiota in local tissues and urine, suggesting a relationship between prostate cancer cells and the gut microbiota. The bacterial composition of the gut microbiota differs depending on prostate cancer characteristics, such as histological grade and castration resistance. Additionally, certain intestinal bacteria have been shown to be involved in testosterone metabolism, indicating a potential influence on prostate cancer progression and treatment. Basic research suggests that the gut microbiome plays a crucial role in prostate cancer biology through microbial-derived metabolites and components. This review focuses on the emerging relationship between the gut microbiome and prostate cancer, referred to as the gut-prostate axis.

WORLD JOURNAL OF MENS HEALTH (2023)

Article Urology & Nephrology

The pressure flow study investigation of pathophysiology of post-micturition dribble in male patients

Mamoru Hashimoto, Nobutaka Shimizu, Saizo Fujimoto, Ken Kuwahara, Mitsuhisa Nishimoto, Shogo Adomi, Eri Banno, Takafumi Minami, Kazutoshi Fujita, Kazuhiro Yoshimura, Akihide Hirayama, Hirotsugu Uemura

Summary: This study aimed to elucidate the pathophysiology of post-micturition dribble (PMD) by analyzing pressure flow study (PFS) findings and symptoms questionnaire. The results showed that PMD was significantly associated with larger prostate volume (PV) and higher bladder outlet obstruction index (BOOI) evaluated by PFS. Furthermore, PMD was found to significantly exacerbate the quality of life (QOL). The severity of PMD and other m-IPSS sub-scores (except nocturia) could have intercorrelation with each other.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2023)

Article Urology & Nephrology

Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer

Naoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, Takafumi Minami, Hideo Tahara, Kazuhiro Yoshimura, Hirotsugu Uemura

Summary: The therapeutic landscape for metastatic hormone-sensitive prostate cancer has changed dramatically, with upfront systemic therapy showing improved survival and quality of life. Future research directions include triplet therapy, local therapy, and personalized treatment.

WORLD JOURNAL OF UROLOGY (2023)

No Data Available